Tibet Weixinkang Medicine Co Ltd Cash Flow Conversion Efficiency
Tibet Weixinkang Medicine Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million ≈ $2.00 Million USD) by net assets (CN¥1.53 Billion ≈ $223.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tibet Weixinkang Medicine Co Ltd (2013–2025)
Cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tibet Weixinkang Medicine Co Ltd stock price for real-time trading data and today's change.
Tibet Weixinkang Medicine Co Ltd Cash Flow Conversion Ratio Explained
Tibet Weixinkang Medicine Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency. Also see Tibet Weixinkang Medicine Co Ltd (603676) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inox Green Energy Services Limited
NSE:INOXGREEN
|
0.015x |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
0.004x |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
0.228x |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
0.021x |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
0.034x |
|
Assure Tech Hangzhou Co Ltd
SHG:688075
|
0.000x |
|
Jiangsu Jiangnan High Polymer Fiber Co Ltd
SHG:600527
|
0.001x |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
N/A |
Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. Review how much free cash does Tibet Weixinkang Medicine Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.48 Billion ≈ $216.04 Million |
CN¥185.53 Million ≈ $27.15 Million |
0.126x | -53.30% |
| 2024-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
CN¥372.78 Million ≈ $54.55 Million |
0.269x | +40.51% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.13 Million |
CN¥256.67 Million ≈ $37.56 Million |
0.191x | -5.04% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.61 Million |
CN¥246.15 Million ≈ $36.02 Million |
0.202x | +26.10% |
| 2021-12-31 | CN¥1.07 Billion ≈ $156.17 Million |
CN¥170.69 Million ≈ $24.98 Million |
0.160x | +17.61% |
| 2020-12-31 | CN¥983.21 Million ≈ $143.87 Million |
CN¥133.70 Million ≈ $19.56 Million |
0.136x | +18.93% |
| 2019-12-31 | CN¥930.05 Million ≈ $136.10 Million |
CN¥106.34 Million ≈ $15.56 Million |
0.114x | +23.41% |
| 2018-12-31 | CN¥897.64 Million ≈ $131.35 Million |
CN¥83.17 Million ≈ $12.17 Million |
0.093x | +25.59% |
| 2017-12-31 | CN¥858.04 Million ≈ $125.56 Million |
CN¥63.30 Million ≈ $9.26 Million |
0.074x | -67.34% |
| 2016-12-31 | CN¥459.42 Million ≈ $67.23 Million |
CN¥103.79 Million ≈ $15.19 Million |
0.226x | -20.48% |
| 2015-12-31 | CN¥402.93 Million ≈ $58.96 Million |
CN¥114.47 Million ≈ $16.75 Million |
0.284x | -31.35% |
| 2014-12-31 | CN¥286.28 Million ≈ $41.89 Million |
CN¥118.47 Million ≈ $17.34 Million |
0.414x | +15.75% |
| 2013-12-31 | CN¥247.78 Million ≈ $36.26 Million |
CN¥88.59 Million ≈ $12.96 Million |
0.358x | -- |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more